Company news
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(688796)"BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD."Report for Q3 2026
October 29, 2026
(688796)"BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD."Announcement on Convening the Q3 2026 Performance Briefing
October 29, 2026
Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2026
September 16, 2026
Announcement on Convening the 2026 Semi-annual Performance Briefing
September 1, 2026
Semi-annual Report for 2026
August 27, 2026
Announcement on Voluntary Disclosure of Semi-annual Performance Forecast for 2026
August 6, 2026
Court Clears Biocytogen’s RenNano® in Landmark Patent Dispute Against Harbour
June 29, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
June 25, 2026
Indicative Announcement on Equity Change of Actual Controllers and Persons Acting in Concert Reaching 1% Scale
June 16, 2026
Announcement on Resolutions of the 18th Meeting of the 2nd Board of Directors
June 4, 2026
Announcement on Circulation of Restricted Stocks in Offline Placement of Initial Public Offering
May 28, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 21, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
May 19, 2026
Announcement on the Investment in the Phase IV Construction Project of BIOCYTOGEN in Nantong, Haimen
April 27, 2026
Special Report on Deposit, Management and Actual Use of Raised Funds in 2025
March 26, 2026
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
February 27, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 26, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
February 12, 2026
Announcement on Expected Increase in Performance for 2025
January 29, 2026
Announcement on the Appointment of Additional Non-Executive Directors and the Adjustment of Members of Special Committees
January 27, 2026
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)
January 9, 2026
Announcement on Resignation of Non-Executive Director
December 31, 2025
Announcement on Resignation of Non-independent Director and Election of Employee Representative Director
December 9, 2025